-
Harbour BioMed’s Anti-CCR8 Monoclonal Antibody HBM1022 Receives FDA IND Approval
•
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced receiving Investigational New Drug (IND) approval from the US FDA for its in-house developed HBM1022, a novel anti-C-C chemokine receptor type 8 (CCR8) monoclonal antibody (mAb). This marks a significant milestone in the…
-
Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study
•
US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for its glucose-dependent insulinotropic polyptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide has reached the primary endpoint and all pivotal secondary endpoints in obese or overweight Chinese adults. The study demonstrated that the overall safety profile was…
-
Lifetech Partners with Jenscare for Structural Heart Disease Devices
•
China-based Lifetech Scientific Corporation (HKG: 1302) has announced a partnership agreement with compatriot firm Jenscare Scientific Co., Ltd. This strategic collaboration aims to enhance the development and marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. Partnership DetailsJenscare, based in Ningbo, is focused on…
-
Gracell’s CAR-T Therapy GC012F Receives FDA IND Approval
•
Shanghai-based biotech Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the US FDA for its chimeric antigen receptor (CAR) T cell candidate GC012F. This dual BCMA/CD19-targeted therapy is set to be assessed in treating relapsed/refractory multiple myeloma (r/r MM), marking a significant step forward in the development…
-
Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results
•
US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial results. Global Q4 sales reached USD 7.4 billion, up 2% year-on-year (YOY), while full-year revenues topped USD 27.3 billion, flat with the previous year. Gilead issued guidance for 2023 product sales to range from USD…
-
Sanofi Reports Strong Q4 and Full-Year 2022 Financials with 7% Growth
•
France’s Sanofi (EPA: SAN) released its financial report last week, showing turnover during Q4 and full-year 2022 at EUR 10.7 billion (USD 11.6 billion) and EUR 43.0 billion (USD 46.4 billion) respectively. This represents year-on-year (YOY) growth of 2.6% and 7.0% at constant exchange rates (CER). The results highlight Sanofi’s…
-
Sanner Group Prepares to Open Second Manufacturing Facility in China
•
Germany-based Sanner Group, a specialist in medical devices and pharma packaging, has announced plans to open a second manufacturing facility in China. This expansion comes alongside the existing facility in Kunshan, Jiangsu Province, and follows the groundbreaking for a new global headquarters and production site in Germany. China Facility DetailsConstruction…
-
Insilico Medicine Opens AI Biotech Research Center in Abu Dhabi
•
China-based AI-powered drug discovery firm Insilico Medicine has revealed the opening of an AI-powered biotechnology research center in Abu Dhabi. This new facility, the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Centre, will offer the firm’s end-to-end AI-driven drug discovery platform, Pharma.AI, and explore aging research…
-
BeiGene Launches Mental Health Program for Cancer Patients
•
China-based biotech BeiGene (Nasdaq: BGNE; HKG: 6160; SHA: 688235) has announced the launch of a new mental health program focused on cancer patients. The “Talk About It: Cancer and Mental Health” program, which includes the website CancerandMentalHealth.com, is designed to ensure that mental health is considered a vital part of…
-
AnHeart Therapeutics Partners with Guardant Health for Taletrectinib Diagnostics
•
Sino-US biopharma AnHeart Therapeutics and US precision oncology firm Guardant Health Inc. (NASDAQ: GH) have unveiled a partnership under which Guardant will provide companion diagnostics in support of AnHeart’s taletrectinib. This collaboration aims to enhance the development, regulatory approval, and commercialization of Guardant360 CDx and Guardant360 TissueNext assays in the…
-
Grand Pharma’s TLX101 Accepted for NMPA Review for Glioblastoma Treatment
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that an Investigational New Drug (IND) filing for its TLX101, a radionuclide drug conjugate (RDC) being developed to treat glioblastoma multiforme, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step in the development…
-
Forlong Biotechnology Secures Series A Funding for Protein Drug Development
•
Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards of RMB 100 million (USD 14.74 million) in a Series A financing round. This significant capital injection will support the company’s ongoing efforts in research and development (R&D), pipeline filing and clinical trials, and business…
-
Haisco Pharmaceutical Announces Public Offering for Clinical Studies
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) is set to make another public offering of 40 million shares, priced at RMB 20 (USD 2.95) per share, to the Shenzhen Stock Exchange. This move aims to raise significant capital for the company’s ongoing drug development initiatives. Use of ProceedsThe proceeds…
-
BDgene’s CRISPR-Cas9 Therapy BD111 Accepted for CDE Review
•
Shanghai BDgene Technology Co., Ltd has announced that a clinical trial filing for its BD111, a CRISPR-Cas9 in vivo-based therapy for herpes simplex virus (HSV)-related keratitis (HSK), has been accepted for review by the Center for Drug Evaluation (CDE). This marks a significant step forward in the development of innovative…
-
JunTop Biosciences’ COVID-19 Therapy Mindewei Priced at RMB 795 per Course
•
Sichuan’s provincial Healthcare Security Administration bureau has notified that Shanghai JunTop Biosciences Co., Ltd’s COVID-19 therapy Mindewei (deuremidevir) is to be initially quoted at RMB 795 (USD 117.23) per treatment course. This pricing announcement marks the entry of Mindewei into the market, offering a new treatment option for mild to…
-
Ji Xing Pharmaceuticals Acquires Global Rights to PhaseBio’s PB6440
•
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global rights to US firm PhaseBio Pharmaceuticals Inc.’s pre-clinical drug candidate PB6440. This strategic partnership aims to advance the development of a next-generation aldosterone synthetase inhibitor (ASi) with significant potential in treating cardiovascular, renal, and metabolic…
-
Mabwell’s Novel ADC 9MW2921 Accepted for NMPA Review
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing for its novel antibody-drug conjugate (ADC) 9MW2921 has been accepted for review by the National Medical Products Administration (NMPA). The firm is seeking to assess the ADC as a treatment for general solid tumors, marking…
-
Amgen Reports Q4 and Full-Year 2022 Financials with Global Sales Growth
•
US major Amgen (NASDAQ: AMGN) has released its Q4 and full-year 2022 financials. Global sales were up 3% year-on-year (YOY) to USD 26.3 billion, excluding foreign exchange impacts. In Q4, sales were relatively flat at 2%, reaching USD 6.8 billion. This performance reflects Amgen’s continued strength in key therapeutic areas…
